Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Raised by Glenview Trust co

Glenview Trust co boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,890 shares of the pharmaceutical company’s stock after purchasing an additional 152 shares during the period. Glenview Trust co’s holdings in Vertex Pharmaceuticals were worth $2,775,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in VRTX. Dunhill Financial LLC raised its position in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth approximately $33,000. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $30,000. Truvestments Capital LLC purchased a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $35,000. Finally, Sugar Maple Asset Management LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at approximately $35,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $504.77 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm’s 50-day moving average is $457.74 and its 200-day moving average is $461.70. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a market cap of $129.62 billion, a price-to-earnings ratio of -229.44, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 244 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares of the company’s stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

VRTX has been the topic of several research analyst reports. Scotiabank boosted their price target on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a “sector perform” rating in a report on Tuesday, February 11th. Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and increased their price objective for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Finally, Piper Sandler reduced their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Ten analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.